Moderating Effects in Randomized Trials-Interpreting the P Value, Confidence Intervals, and Hazard Ratios

被引：6

作者：

Agarwal, Rajiv ^{[1
,2
]}

Rifkin, Brian ^{[3
]}

机构：

[1] Indiana Univ Sch Med, Div Nephrol, Dept Med, Indianapolis, IN 46202 USA

[2] Richard L Roudebush Vet Adm Med Ctr, 1481 West 10th St,111N, Indianapolis, IN 46202 USA

[3] Hattiesburg Clin, Div Nephrol, Hattiesburg, MS USA

来源：

KIDNEY INTERNATIONAL REPORTS | 2022年 / 7卷 / 03期

关键词：

D O I：

10.1016/j.ekir.2022.01.1049

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：371 / 374

页数：4

共 8 条

[1]

Agarwal R, 2022, EUR HEART J

[2] Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes [J].

Bakris, George L. ;

Agarwal, Rajiv ;

Anker, Stefan D. ;

Pitt, Bertram ;

Ruilope, Luis M. ;

Rossing, Peter ;

Kolkhof, Peter ;

Nowack, Christina ;

Schloemer, Patrick ;

Joseph, Amer ;

Filippatos, Gerasimos .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2219-2229

[3] Dapagliflozin in Patients with Chronic Kidney Disease [J].

Heerspink, Hiddo J. L. ;

Stefansson, Bergur V. ;

Correa-Rotter, Ricardo ;

Chertow, Glenn M. ;

Greene, Tom ;

Hou, Fan-Fan ;

Mann, Johannes F. E. ;

McMurray, John J. V. ;

Lindberg, Magnus ;

Rossing, Peter ;

Sjostrom, C. David ;

Toto, Roberto D. ;

Langkilde, Anna-Maria ;

Wheeler, David C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1436-1446

[4] Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage [J].

Kolkhof, Peter ;

Hartmann, Elke ;

Freyberger, Alexius ;

Pavkovic, Mira ;

Mathar, Ilka ;

Sandner, Peter ;

Droebner, Karoline ;

Joseph, Amer ;

Hueser, Jorg ;

Eitner, Frank .

AMERICAN JOURNAL OF NEPHROLOGY, 2021, 52 (08) :642-652

[5] Mediators and moderators of treatment effects in randomized clinical trials [J].

Kraemer, HC ;

Wilson, GT ;

Fairburn, CG ;

Agras, WS .

ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (10) :877-883

[6] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [J].

Perkovic, V. ;

Jardine, M. J. ;

Neal, B. ;

Bompoint, S. ;

Heerspink, H. J. L. ;

Charytan, D. M. ;

Edwards, R. ;

Agarwal, R. ;

Bakris, G. ;

Bull, S. ;

Cannon, C. P. ;

Capuano, G. ;

Chu, P. -L. ;

De Zeeuw, D. ;

Greene, T. ;

Levin, A. ;

Pollock, C. ;

Wheeler, D. C. ;

Yavin, Y. ;

Zhang, H. ;

Zinman, B. ;

Meininger, G. ;

Brenner, B. M. ;

Mahaffey, K. W. ;

McGuire, Darren K. ;

Holman, Rury ;

Home, Philip ;

Scharfstein, Dan ;

Parfrey, Patrick ;

Shahinfar, Shahnaz ;

August, Phyllis ;

Chang, Tara ;

Sinha, Arjun D. ;

Januzzi, James ;

Kolansky, Daniel ;

Amerena, John ;

Hillis, Graham ;

Gorelick, Philip ;

Kissela, Brett ;

Kasner, Scott ;

Lindley, Richard ;

Fulcher, Greg ;

Ounadjela, Souhila ;

Hufert, Karina ;

von Ingersleben, Gabriele ;

Gaglia, Jason ;

Harris, Ronald ;

Hudson, Margo ;

Turchin, Alexander ;

Cheifetz, Adam .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) :2295-2306

[7] The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists [J].

Provenzano, Michele ;

Jongs, Niels ;

Vart, Priya ;

Stefansson, Bergur, V ;

Chertow, Glenn M. ;

Langkilde, Anna Maria ;

McMurray, John J., V ;

Correa-Rotter, Ricardo ;

Rossing, Peter ;

Sjostrom, C. David ;

Toto, Robert D. ;

Wheeler, David C. ;

Heerspink, Hiddo J. L. .

KIDNEY INTERNATIONAL REPORTS, 2022, 7 (03) :436-443

[8] Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy [J].

Rossing, Peter ;

Filippatos, Gerasimos ;

Agarwal, Rajiv ;

Anker, Stefan D. ;

Pitt, Bertram ;

Ruilope, Luis M. ;

Chan, Juliana C. N. ;

Kooy, Adriaan ;

McCafferty, Kieran ;

Schernthaner, Guntram ;

Wanner, Christoph ;

Joseph, Amer ;

Scheerer, Markus F. ;

Scott, Charlie ;

Bakris, George L. .

KIDNEY INTERNATIONAL REPORTS, 2022, 7 (01) :36-45

← 1 →